ClinicalTrials.gov
public full text
Public Domain
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Fundus Ablation Registry (Gastric Fundus Mucosal Ablation for Weight Loss)#1088852
- Fat Supplementation on Dumping Syndrome Associated Symptoms#1164187
- Evaluation of Surgical Complications and DFS in Obese Rectal Cancer Patients#813467
- Effect of GLP-1 on Postprandial Lipid Metabolism#1211580
- A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range#894938
Record · ID 1195630
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive